CLIP - Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Methods Mol Biol. 2022;2453:91-99. doi: 10.1007/978-1-0716-2115-8_6.
Selection of the proper target is crucial for clinically relevant monitoring of minimal residual disease (MRD) in patients with acute lymphoblastic leukemia using the quantitation of clonal-specific immunoreceptor (immunoglobulin/T cell receptor) gene rearrangements. Consequently, correct interpretation of the results of the entire analysis is of utmost importance. Here we present an overview of the quality control measures that need to be implemented into the process of marker identification, selection, and subsequent quantitation of the MRD level.
选择合适的靶标对于使用克隆特异性免疫受体（免疫球蛋白/T 细胞受体）基因重排定量来监测急性淋巴细胞白血病患者的微小残留病（MRD）至关重要。因此，正确解释整个分析结果至关重要。在这里，我们介绍了在标记物鉴定、选择和随后的 MRD 水平定量过程中需要实施的质量控制措施概述。
